公开(公告)号：US20220347143A1

公开(公告)日：2022-11-03

申请号：US17837666

申请日：2022-06-10

申请人： ENTRINSIC, INC. ,  UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

发明人： Sadasivan VIDYASAGAR ,  Stephen J. GATTO ,  Daniel B. DENNISON

IPC分类号： A61K31/198 ,  A61K31/197 ,  A61K31/405 ,  A61P1/00 ,  A61P1/12 ,  A61P3/12 ,  A61P29/00 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00

摘要： The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of symptoms of a disease selected from the group consisting of: Ebola virus infection, HIV infection, ataxia, environmental enteropathy, cancer, hangover, inflammatory disease, and porcine epidemic diarrhea. In preferred embodiments, the composition includes a combination of one or more amino acids selected from the group comprising lysine, aspartic acid, glycine, isoleucine, threonine, tyrosine, valine, tryptophan, asparagine and/or serine.

公开(公告)号：US11485724B2

公开(公告)日：2022-11-01

申请号：US16464224

申请日：2017-11-23

申请人： Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd ,  Ganzhou Hemay Pharmaceutical, Co., Ltd

发明人： Hesheng Zhang ,  Guanghuai Zeng

IPC分类号： C07D401/04 ,  A61P1/00 ,  A61P1/04 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

摘要： Disclosed are piperidine-2,6-dione derivatives and treatment of ulcerative colitis.

公开(公告)号：US11479588B2

公开(公告)日：2022-10-25

申请号：US17529396

申请日：2021-11-18

申请人： Jiangnan University

发明人： Jia Sun ,  Li-Long Pan ,  Diana Julien ,  Ming Zhang ,  Wei Chen ,  Hao Zhang

IPC分类号： A61K35/747 ,  A61K35/00 ,  C07K14/47 ,  A23L33/135 ,  A61P1/00 ,  A61K39/00

摘要： The disclosure discloses cathelicidin-expressing lactic acid bacteria, and belongs to the technical field of genetic engineering. The disclosure constructs Lactococcus. lactis and Lactobacillus. plantarum expressing a CRAMP protein by optimizing the nucleotide sequence of the CRAMP protein. The Lactobacillus constructed in the disclosure can be used to prepare a vaccine for regulation of intestinal flora disorder, and has advantages in regulation of intestinal flora and intestinal immune response and maintenance. An anaculture can be directly taken as an oral vaccine to stimulate mice and cause a strong cellular immune response. The recombinant L. lactis can be used as a new oral vaccine product with good industrial prospects, plays a positive role in reducing intestinal inflammation, and has important practical significance for promoting health development of the intestinal tract.

公开(公告)号：US11459382B2

公开(公告)日：2022-10-04

申请号：US16614582

申请日：2018-05-21

申请人： Alexion Pharmaceuticals, Inc.

发明人： Orly Eshach Adiv ,  Camille Bedrosian ,  Hagit Baris Feldman ,  Alina Kurolap ,  Susan Faas McKnight

IPC分类号： C07K16/18 ,  A61P1/00 ,  A61K39/00

摘要： Provided are methods for clinical treatment of a protein-losing enteropathy, such as lymphangiectasia, using an anti-C5 antibody, or antigen binding fragment thereof, in patients (e.g., pediatric patients).

公开(公告)号：US11458162B2

公开(公告)日：2022-10-04

申请号：US17315164

申请日：2021-05-07

申请人： Robert Olson ,  Deshka Olson ,  Wayne Provost

发明人： Robert Olson ,  Deshka Olson ,  Wayne Provost

IPC分类号： A61K33/14 ,  A61K9/00 ,  A61K9/14 ,  A61K47/12 ,  A61P1/00 ,  A61P43/00

摘要： The present invention relates to compositions and methods for controlling a gag reflex in a patient.

公开(公告)号：US11453666B2

公开(公告)日：2022-09-27

申请号：US16826046

申请日：2020-03-20

申请人： Cancer Research Technology Limited

发明人： Martin Lee Stockley ,  Ellen Catherine Macdonald ,  Pritom Shah ,  Allan Jordan ,  James Hitchin ,  Niall Hamilton

IPC分类号： A61P1/00 ,  A61P1/16 ,  A61P29/00 ,  A61P31/20 ,  A61P31/14 ,  A61P31/12 ,  A61P3/10 ,  A61P7/12 ,  A61P17/00 ,  A61P17/04 ,  A61P17/02 ,  A61P35/00 ,  A61P35/02 ,  A61P7/04 ,  A61P7/02 ,  A61P13/02 ,  A61P13/12 ,  A61P9/12 ,  A61P9/00 ,  A61P43/00 ,  A61P19/04 ,  A61K31/5025 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/404 ,  A61K31/551 ,  A61K31/55 ,  A61K31/496 ,  A61K31/4184 ,  A61K45/06 ,  C07D235/02 ,  C07D471/04 ,  A61K31/437

摘要： The present invention relates to compounds of formula I wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.

公开(公告)号：US11439670B2

公开(公告)日：2022-09-13

申请号：US17258510

申请日：2020-05-11

申请人： ENTEROBIOME INC.

发明人： Jae-Gu Seo ,  Joo-Hyun Shin ,  Do-Kyung Lee

IPC分类号： A61K35/74 ,  A23L33/00 ,  A23L33/135 ,  A61P1/00 ,  C12N1/20

摘要： Disclosed are a novel Akkermansia muciniphila EB-AMDK27 strain having the effect of preventing or treating inflammatory disease or metabolic disease, and a pharmaceutical composition effective for preventing or treating inflammatory disease or metabolic disease, which contains the strain, a culture thereof, or a dried product thereof. While traditional probiotics generally have insufficient therapeutic effects on inflammatory or metabolic diseases, the disclosed next generation probiotic strain has an excellent effect on the prevention or treatment of inflammatory disease and/or metabolic disease so that it may be used as a new prophylactic and therapeutic tool.

公开(公告)号：US20220273763A1

公开(公告)日：2022-09-01

申请号：US17740547

申请日：2022-05-10

申请人： OHIO STATE INNOVATION FOUNDATION

发明人： Jianjie MA ,  Chunyu ZENG ,  Yu HAN ,  Donghai YANG ,  Zhengfang GONG ,  Zhongshu ZHOU ,  Jin ZHONG

IPC分类号： A61K38/17 ,  A61K35/747 ,  A61P1/00 ,  A61K9/00 ,  A23L33/00 ,  A23L33/195 ,  A23L33/135

摘要： Compositions for and methods of treating irritable bowel disease are provided. The compositions and methods employ MG53, which can be in the form of recombinant human MG53. The MG53 can be administered in a form to avoid or bypass gastric digestion or degradation. The composition can include a live MG53-expressing microbe, such as a probiotic composition that expresses MG53 in the gastrointestinal tract of a subject. An enteric release composition comprising MG53 is also provided.

公开(公告)号：US20220273665A1

公开(公告)日：2022-09-01

申请号：US17357625

申请日：2021-06-24

申请人： CEDARS-SINAI MEDICAL CENTER

发明人： Dermot MCGOVERN ,  Dalin LI ,  Janine BILSBOROUGH

IPC分类号： A61K31/5377 ,  A61K31/5025 ,  A61K31/44 ,  A61K31/517 ,  A61P1/00

摘要： Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis in a subject, with an antagonist of RIPK2 activity or expression. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with the antagonist to RIPK2 activity or expression, as described herein.

公开(公告)号：US20220273640A1

公开(公告)日：2022-09-01

申请号：US17637491

申请日：2020-07-10

申请人： Fujian Medical University

发明人： Jian YANG ,  Changxi YU ,  Ying XU ,  Huihui HUANG

IPC分类号： A61K31/475 ,  A61P1/00

摘要： The present invention relates to novel use of koumine, an alkaloid monomer from Gelsemium elegans Benth., or a pharmaceutically acceptable salt thereof, and more particularly to use of koumine or its pharmaceutically acceptable salt in the preparation of a medicament for the treatment of inflammatory bowel disease.